BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed ...
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on January 14th, the Representative disclosed that they had sold between ...
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations, as wholesalers cut inventory after bulking up on supply in the previous ...
The multinational pharmaceutical company had previously used distribution and promotion agreements with Eli Lilly to market the Huminsulin line of products. Indian pharma giant Lupin's shares ...
Global pharma major Lupin Limited on Monday announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. “The Huminsulin range ...